{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:25:39Z","timestamp":1760909139857},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Intrahepatic cholangiocarcinoma (ICC) originates from the secondary branch of the bile duct and the intrahepatic bile duct epithelial cells, and is a rare pathological type of primary liver cancer. Recently, apatinib has been successfully used for a variety of malignancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 23-year-old female was noted with intermittent right upper abdominal distension, abdominal pain, and vomiting after eating for more than 1 month. The enhanced CT scan revealed multiple intrahepatic lesions, portal vein and right branch tumor emboli were present.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Combined with the patient's medical history and pathology and immunohistochemistry, the diagnosis was confirmed as locally advanced unresectable ICC (cT4N1M1, Stage IVB).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The disease progressed after six cycles of gemcitabine plus capecitabine chemotherapy. She received oral apatinib treatment since September 30, 2017. Due to related adverse reactions, the patient could not tolerate the treatment, and the subsequent reduction therapy was given.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>On April 11, 2018, the review of CT evaluation suggested that the disease was progressed. Hence, in this patient, apatinib as second-line treatment for advanced ICC showed a progression-free survival with 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Apatinib as second-line treatment for advanced ICC is effective, and the adverse effects are tolerable. However, the efficacy and safety of apatinib in the treatment of ICC need to be further confirmed by large sample of prospective randomized controlled trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013372","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:09:10Z","timestamp":1544292550000},"page":"e13372","source":"Crossref","is-referenced-by-count":9,"title":["Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy"],"prefix":"10.1097","volume":"97","author":[{"given":"Li-Ye","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Xia","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20240524","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.bjc.6603127","article-title":"Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971\u20132001","volume":"94","author":"West","year":"2006","journal-title":"Br J Cancer"},{"key":"R2-20240524","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4254\/wjh.v2.i2.58","article-title":"Surgery and chemotherapy for intrahepatic cholangiocarcinoma","volume":"2","author":"Morise","year":"2010","journal-title":"World J Hepatol"},{"key":"R3-20240524","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.suronc.2017.03.001","article-title":"Multidisciplinary management of intrahepatic cholangiocarcinoma: current approaches","volume":"26","author":"Guro","year":"2017","journal-title":"Surg Oncol"},{"key":"R4-20240524","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.2147\/DDDT.S97235","article-title":"Apatinib for molecular targeted therapy in tumor","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"R5-20240524","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"R6-20240524","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jtho.2016.02.020","article-title":"Icotinib in patients with pretreated advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: a single-arm, multicenter phase 2 study","volume":"11","author":"Huang","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R7-20240524","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ajco.12834","article-title":"Clinical response to apatinib monotherapy in advanced non-small cell lung cancer","volume":"14","author":"Xu","year":"2018","journal-title":"Asia-Pac J Clin Oncol"},{"key":"R8-20240524","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.3748\/wjg.v23.i41.7478","article-title":"Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: a case report and literature review","volume":"23","author":"Li","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R9-20240524","first-page":"990","article-title":"Apatinib has anti-tumor effects and induces autophagy in colon cancer cells","volume":"20","author":"Lu","year":"2017","journal-title":"Iran J Basic Med Sci"},{"key":"R10-20240524","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.2147\/OTT.S110235","article-title":"Successful treatment of angiosarcoma of the scalp with apatinib: a case report","volume":"9","author":"Ji","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R11-20240524","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1001\/jama.2009.1755","article-title":"Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases","volume":"302","author":"Chun","year":"2009","journal-title":"JAMA"},{"key":"R12-20240524","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1023\/A:1013747228572","article-title":"Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy","volume":"12","author":"Donato","year":"2001","journal-title":"Cancer Causes Control"},{"key":"R13-20240524","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-013-2106-0","article-title":"A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer","volume":"71","author":"Suzuki","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R14-20240524","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10637-010-9417-3","article-title":"Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness","volume":"29","author":"Oh","year":"2011","journal-title":"Investig New Drugs"},{"key":"R15-20240524","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s10637-010-9485-4","article-title":"Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer","volume":"29","author":"Sasaki","year":"2011","journal-title":"Investig New Drugs"},{"key":"R16-20240524","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3748\/wjg.v21.i7.2096","article-title":"FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma","volume":"21","author":"Guion-Dusserre","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R17-20240524","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jhep.2017.07.006","article-title":"Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice","volume":"67","author":"Zhang","year":"2017","journal-title":"J Hepatol"},{"key":"R18-20240524","doi-asserted-by":"crossref","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"key":"R19-20240524","doi-asserted-by":"crossref","first-page":"19513","DOI":"10.1073\/pnas.1311707110","article-title":"Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target","volume":"110","author":"Saborowski","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"R20-20240524","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"R21-20240524","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients \u2018II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br J Cancer"},{"key":"R22-20240524","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"R23-20240524","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"El-Khoueiry","year":"2014","journal-title":"Br J Cancer"},{"key":"R24-20240524","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"R25-20240524","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"R26-20240524","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br J Cancer"},{"key":"R27-20240524","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J Clin Oncol"},{"key":"R28-20240524","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2741\/3796","article-title":"Vasculogenensis, angiogenesis and special features of tumor blood vessels","volume":"16","author":"Hiratsuka","year":"2011","journal-title":"Front Biosci"},{"key":"R29-20240524","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R30-20240524","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1634\/theoncologist.12-11-1332","article-title":"Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature","volume":"12","author":"Rajasekhar","year":"2007","journal-title":"Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:01:07Z","timestamp":1716584467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812070-00041"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013372","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}